Signaling Gateway - 18 April 2008
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0M40ED
*********************************************************************
Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.
*********************************************************************
BIORAD
The Profinity eXact(TM) fusion-tag system consists
of an integrated set of products that enables
single-step purification and tag cleavage in as
little as 60 minutes, with no cleavage enzymes,
lengthy incubations, or removal of reagents.
For more information, visit:
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2r0En
*********************************************************************
In Signaling Update this week:
------------------------
Featured Article
------------------------
TNF SIGNALING: THE LONG RUN TO ARTHRITIS
Tumor necrosis factor (TNF) stimulation primes macrophages for higher
inflammatory responses through an interferon-response factor 1 (IRF1-)
and interferon beta- (IFN-beta-)mediated autocrine loop similar to
that used by toll-like receptors (TLRs).
Original research paper: Nat. Immunol. 9, 378-387 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0vP0EM
-------------------
Selected Updates
-------------------
APOPTOSIS: BIM AND FAS: THE ULTIMATE DEATH SQUAD
Three studies have shown that the cell-extrinsic (BIM-induced) and
cell-intrinsic (FAS-induced) pathways cooperate to maintain
homeostasis, prevent autoimmunity and terminate immune responses.
Original research paper: Immunity 28, 197-205 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2s0Eo
TUMOUR SUPPRESSORS: SPREAD YOUR WINGS
The E2F1 transcription factor has been identified as an oncogenic
target of the Salvador (SAV)-Warts(WTS)-Hipp(HPO) tumor suppressor
pathway.
Original research paper: Curr. Biol. 18, 435-441 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2t0Ep
PSYCHIATRIC DISORDERS: DOUBLE GPCR TROUBLE
The potential and confirmed anti-psychotic drug targets metabotropic
type-2 glutamate receptor (mGluR2) and 5-hydroxytryptamine 2A receptor
(5-HT2AR) have been found to form a complex that might be involved in
schizophrenia.
Original research paper: Nature 452, 93-97 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2u0Eq
More Updates:
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0vO0EL
------------------------
Research Library
------------------------
INTEGRATION OF GROWTH AND SPECIFICATION IN CHICK WING
DIGIT-PATTERNING
Nature 452, 882-886 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2v0Er
COMPARTMENT-SPECIFIC TRANSCRIPTION FACTORS ORCHESTRATE ANGIOGENESIS
GRADIENTS IN THE EMBRYONIC BRAIN
Nature Neuroscience 11, 829-839 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2w0Es
DROSOPHILA STAT IS REQUIRED FOR DIRECTLY MAINTAINING HP1 LOCALIZATION
AND HETEROCHROMATIN STABILITY
Nature Cell Biology 10, 489-496 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2x0Et
------------------------
Signaling News
------------------------
JAMES WATSON'S GENOME SEQUENCED AT HIGH SPEED
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bsq40Eo
The first full genome has been sequenced using next-generation
rapid-sequencing technology. It took just four months, a handful of
scientists and less than US$1.5 million to sequence the 6 billion
base pairs of DNA pioneer James Watson and has been marked as a
milestone in human genome sequencing. But the identification of
genomic alterations that carry a disease risk still remains a
challenge for personal sequencing.
More News
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Crw0E3
-------------------------
Gateway Updates
-------------------------
THE FUNCTIONAL GLYCOMICS GATEWAY - APRIL UPDATE
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BKHW0E3
The Functional Glycomics Gateway is a comprehensive FREE online
resource to keep you abreast of the latest findings in the field.
This month's update features:
T-cell development: The sweet face of death
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BsUx0EU
and
Migration and anergy: The lattice strikes again
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BsU30EL
Sign up to receive the monthly table of contents e-alert for the
Functional Glycomics Update.
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BJYw0Eq
-----------------------------
Signaling Job of the Week
-----------------------------
Chair, Department of Biochemistry
Employer: Boston University
Location: Boston, MA, USA
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0Bs2y0Eu
Boston University School of Medicine invites applications for a
visionary leader to chair the Department of Biochemistry. The
successful applicant will lead the Department in all academic
endeavors, including the education of medical, dental and graduate
students and maintain a successful research program. Candidates should
have a distinguished record of scientific achievement, training and
mentoring, grant support, and national and international professional
involvement.
More Jobs:
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BnjC0Er
To advertise a job in this spot, please contact Naturejobs.
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0vqs0Eo
======================================================================
Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway.
Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0dIO0EG
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.
If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BCGZ0Ew
For further technical assistance or any other enquiries, please click here:
http://ealerts.nature.com/cgi-bin24/DM/y/ekMp0Xztnp0H2W0BByD0EP
Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston
(c) 2008 Nature Publishing Group
---------------------------------------------------------------------
